Emma Andrus, Editor

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C discuss the NEA's expanded eczema visual guide and upcoming Chicago event to support diverse patient communities.

EltaMD’s Derm Difference campaign honors dermatologists’ expertise in skin health, cancer prevention, and confidence-boosting care.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C, discuss redefining eczema flares to align clinical and patient perspectives.

The agency shared details of additional voluntary recalls and its plans to release full results of its independent testing in the coming months.

Renata Block, MMS, PA-C, speaks with Wendy Smith Begolka, MBS, of the National Eczema Association about NEA’s strategic efforts in community outreach, health care provider engagement, and patient education.

This review of the latest dermatologic studies includes insights into erectile dysfunction in dermatology and venereology, diet and psoriasis information on TikTok, and more.

Test your knowledge of key words and terms associated with dermatology meeting news from the previous week.

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

The phase 2 trial of bimiralisib gel shows promising efficacy and safety for actinic keratosis, with up to 70% lesion clearance.

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

Among the many sessions to be held at the American Academy of Dermatology Annual Meeting in Orlando, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

Experts discussed laser and light-based therapies for acne, rosacea, hyperpigmentation, and inflammatory skin diseases.